IP Library Granted Patent US 7,560,533
Granted Patent B2
US 7,560,533 · App. 10/246,853 · Granted Jul 14, 2009

Binding compounds specific for cysteine-rich soluble protein C23

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,560,533
App. No.
10/246,853
Granted
Jul 14, 2009
Kind
B2
Abstract

Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

Claims (14)

1. An isolated binding compound comprising an isolated antibody or an antigen binding portion thereof that specifically binds to a polypeptide consisting of the amino acid sequence of the C23 polypeptide of SEQ ID NO: 2.

2. A kit comprising:

a) said binding compound of claim 1 ;

b) a compartment for containing said binding compound; and

c) instructions for use of said binding compound.

3. A method of making an antibody of claim 1 , comprising immunizing a mammal with an immunogenic amount of a C23 polypeptide of SEQ ID NO: 2 thereby causing said antibody to be produced.

4. A composition comprising the binding compound of claim 1 and a carrier, wherein said carrier comprises water, saline, and buffer.

5. The binding compound of claim 1 , wherein the antibody specifically binds to a polypeptide consisting of amino acid residues 1-90 of SEQ ID NO: 2.

6. The binding compound of claim 1 , wherein the antigen binding portion is an Fv, Fab, or Fab2 fragment.

7. The binding compound of claim 1 , wherein the binding compound is detectably labeled.

8. The binding compound of claim 7 , wherein the binding compound is detectably labeled with a radioactive or fluorescent label.

9. A method of producing an antigen:antibody complex, comprising contacting a C23 polypeptide with an antibody of claim 1 thereby allowing said complex to form.

10. A composition comprising the binding compound of claim 1 and a carrier, wherein said composition is formulated for oral, rectal, nasal, topical, or parenteral administration.

11. The binding compound of claim 1 wherein the antibody is chimeric or humanized.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →